Tech Company Financing Transactions
Zelluna Immunotherapy Funding Round
Private investors joined a $1.6 million funding round for Zelluna Immunotherapy. The financing round was announced on 6/30/2026.
Transaction Overview
Company Name
Announced On
6/30/2026
Transaction Type
Debt
Amount
$1,600,000
Round
Undisclosed
Investors
Proceeds Purpose
Funding will support Zelluna's ongoing Phase 1 clinical study, ZIMA-101
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Oslo Cancer Cluster Innovation Park Ullernchausséen 64
Oslo, 0379
Norway
Oslo, 0379
Norway
Phone
Website
Email Address
Overview
Zelluna Immunotherapy is a biopharma company developing "off-the-shelf" T-cell receptor (TCR) guided natural killer (NK) cell therapy products for the treatment of multiple solid cancers. We are an expanding team of committed professionals who are constantly striving to improve the lives of patients and their families by developing new transformative treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Hans Robinson
Chief Executive Officer
Namir Hassan
Chief Financial Officer
Geir Melen
Chief Operating Officer
Anders Holm
Browse more venture capital transactions:
Prev: 6/30/2026: Trussed AI venture capital transaction
Next: 6/30/2026: Jota Plataforma venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs